93 related articles for article (PubMed ID: 6949642)
1. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
2. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
Reilly KM; Kisor DF
Onco Targets Ther; 2009 Feb; 2():219-28. PubMed ID: 20616909
[TBL] [Abstract][Full Text] [Related]
3. Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action.
Derissen EJB; Beijnen JH
Clin Pharmacokinet; 2020 Dec; 59(12):1521-1550. PubMed ID: 33064276
[TBL] [Abstract][Full Text] [Related]
4. Loss of KDM6A confers drug resistance in acute myeloid leukemia.
Stief SM; Hanneforth AL; Weser S; Mattes R; Carlet M; Liu WH; Bartoschek MD; Domínguez Moreno H; Oettle M; Kempf J; Vick B; Ksienzyk B; Tizazu B; Rothenberg-Thurley M; Quentmeier H; Hiddemann W; Vosberg S; Greif PA; Metzeler KH; Schotta G; Bultmann S; Jeremias I; Leonhardt H; Spiekermann K
Leukemia; 2020 Jan; 34(1):50-62. PubMed ID: 31201358
[TBL] [Abstract][Full Text] [Related]
5. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.
Herold N; Rudd SG; Sanjiv K; Kutzner J; Bladh J; Paulin CBJ; Helleday T; Henter JI; Schaller T
Cell Cycle; 2017 Jun; 16(11):1029-1038. PubMed ID: 28436707
[TBL] [Abstract][Full Text] [Related]
6. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
Zhang W; Ding Y; Wu H; Chen Y; Lu H; Chen C; Fu J; Wang W; Liang A; Zou S
Medicine (Baltimore); 2014 Dec; 93(27):e134. PubMed ID: 25501050
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced cerebellar ataxia: a systematic review.
van Gaalen J; Kerstens FG; Maas RP; Härmark L; van de Warrenburg BP
CNS Drugs; 2014 Dec; 28(12):1139-53. PubMed ID: 25391707
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Fathi AT; Chen YB
Curr Hematol Malig Rep; 2014 Jun; 9(2):186-92. PubMed ID: 24643311
[TBL] [Abstract][Full Text] [Related]
10. Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.
Momparler RL
Exp Hematol Oncol; 2013; 2():20. PubMed ID: 23919448
[TBL] [Abstract][Full Text] [Related]
11. High-dose cytarabine (HD araC) in the treatment of leukemias: a review.
Reese ND; Schiller GJ
Curr Hematol Malig Rep; 2013 Jun; 8(2):141-8. PubMed ID: 23666364
[TBL] [Abstract][Full Text] [Related]
12. Implications of therapy-induced selective autophagy on tumor metabolism and survival.
Hughson LR; Poon VI; Spowart JE; Lum JJ
Int J Cell Biol; 2012; 2012():872091. PubMed ID: 22550492
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.
Johnson SA
Clin Pharmacokinet; 2000 Jul; 39(1):5-26. PubMed ID: 10926348
[TBL] [Abstract][Full Text] [Related]
14. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.
Marsh JH; Kreis W; Barile B; Akerman S; Schulman P; Allen SL; DeMarco LC; Schuster MW; Budman DR
Cancer Chemother Pharmacol; 1993; 31(6):481-4. PubMed ID: 8453688
[TBL] [Abstract][Full Text] [Related]
15. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
16. A phase I-II study of combination therapy with thymidine and cytosine arabinoside.
Fram R; Major P; Egan E; Beardsley P; Rosenthal D; Kufe D
Cancer Chemother Pharmacol; 1983; 11(1):43-7. PubMed ID: 6883625
[TBL] [Abstract][Full Text] [Related]
17. High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma.
Rohatiner A; Slevin ML; Dhaliwal HS; Malpas JS; Lister TA
Cancer Chemother Pharmacol; 1984; 12(2):90-3. PubMed ID: 6697429
[TBL] [Abstract][Full Text] [Related]
18. Synergistic killing of human leukaemic lymphoblasts by glucocorticoids and cytosine arabinoside.
Gledhill RM; Edwards AJ; Norman MR
Br J Cancer; 1983 May; 47(5):649-57. PubMed ID: 6573907
[TBL] [Abstract][Full Text] [Related]
19. Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia.
Yang JL; Cheng EH; Capizzi RL; Cheng YC; Kute T
J Clin Invest; 1985 Jan; 75(1):141-6. PubMed ID: 4038404
[TBL] [Abstract][Full Text] [Related]
20. Central nervous system pharmacokinetics of high-dose cytosine arabinoside.
Lopez JA; Nassif E; Vannicola P; Krikorian JG; Agarwal RP
J Neurooncol; 1985; 3(2):119-24. PubMed ID: 4031970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
